Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity

Figure 6

Inhibition of tumor angiogenesis. Tumor angiogenesis analysis was performed by CD31 staining. Significant reduction in new blood vessel formation (black arrows) was observed in HB-002.1 treated Colo-205 (A) as well as A549 (B) tumors, respectively. Representative fields of CD31 staining in tumors treated with PBS (left) or doxorubicin (upper middle) or HB-002.1 (right) are shown at 40x magnification (40X).

Back to article page
\